 |
|
Therapeutic Efficacy of Phenytoin in Recessive Dystrophic EpidermolysisA Comparison of Short- and Long-term Treatment
Thomas W. Cooper, MD;
Eugene A. Bauer, MD
Arch Dermatol. 1984;120(4):490-495.
Abstract
• To assess the potential short- and long-term efficacy of phenytoin in treating recessive dystrophic epidermolysis bullosa (RDEB), we treated 22 patients with therapeutic doses of oral phenytoin (blood level, 8 to 10 µg/mL for periods ranging from eight to 99 weeks. Fourteen (64%) of the 22 patients had greater than a 40% mean percentage decrease in blistering of the skin. Nine (41%) of the 22 patients were treated for longer than 75 weeks, and seven (78%) of these nine patients had a mean decrease in blistering of at least 40% during phenytoin therapy. These data, along with previous reports, suggest that phenytoin has therapeutic efficacy in RDEB.
(Arch Dermatol 1984;120:490-495)
Author Affiliations
From the Division of Dermatology, Department of Medicine, Washington University School of Medicine, St Louis.
Footnotes
Accepted for publication Oct 17, 1983.
Reprint requests to the Division of Dermatology, Department of Medicine, Washington University School of Medicine, Box 8123, 4950 Audubon Ave, St Louis, MO 63110 (Dr Bauer).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Tetracyclines Inhibit Connective Tissue Breakdown: New Therapeutic Implications for an Old Family of Drugs
Golub et al.
CROBM 1991;2:297-321.
ABSTRACT
| FULL TEXT
Efficacy of Systemic Phenytoin in the Treatment of Junctional Epidermolysis Bullosa
Fine and Johnson
Arch Dermatol 1988;124:1402-1406.
ABSTRACT
Recessive Dystrophic Epidermolysis Bullosa
Destro et al.
Arch Ophthalmol 1987;105:1248-1252.
ABSTRACT
|
